Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study

BACKGROUND: Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR). METHODS: This was a phase II, multicenter, double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Norio, Mobashery, Niloufar, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318982/
https://www.ncbi.nlm.nih.gov/pubmed/25115901
http://dx.doi.org/10.1007/s00535-014-0979-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318982/
https://www.ncbi.nlm.nih.gov/pubmed/25115901
http://dx.doi.org/10.1007/s00535-014-0979-2

Ejemplares similares